Norepinephrine increases myocardial contractility and myocardial oxygen consumption (MVO 2 ). It is not clear whether these phenomena are directly proportional or whether there is a disproportionate increase in MVO 2 , signifying either uncoupling of oxidative phosphorylation or a direct increase in oxidative metabolism. Accordingly, the direct conversion of chemical energy to mechanical work was studied in control and norepinephrine-treated right ventricular papillary muscles from cats. Production of adenosine triphosphate (ATP) was inhibited by iodoacetic acid and N 2 . After resting or performing variable amounts of work, the muscles were instantly frozen, and the total amount of chemical energy ( * -P = creatine phosphate + ATP) used was correlated with work performed and the number of contractions. There was no change in either the initial stores of energy or in the basal rate of energy utilization following treatment with norepinephrine. However, norepinephrine-treated muscles performing isometric work used 115% as much ~P as control muscles in only 5956 as many contractions and while performing only 8735 as much work. Regression analysis of these data confirmed that norepinephrine-treated muscles used a greater amount of -P than do control muscles. Thus the increase in contractility induced by norepinephrine results in an increase in the amount of chemical energy released disproportionate to the amount of work performed, and the "oxygen wasting" effect of norepinephrine on heart muscle results from the increased utilization of energy associated with an increased contractile state.
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• Norepinephrine increases the contractile state of heart muscle as characterized by an increase in shortening velocity and force of contraction (1) . Recent studies indicate that these effects of norepinephrine are accompanied by increased myocardial oxygen consumption (MVOo) and therefore increased energy utilization (2) . However, the mecha-nisms for this increase in oxygen consumption are not clear. In addition to a direct effect of catecholamines on mechanical activity, leading to an increase in MVO 2 , uncoupling of oxidative phosphorylation and a direct increase in oxidative metabolism have been suggested (3). In resting heart muscle, norepinephrine and other catecholamines have been shown to produce minimal changes in basal oxygen consumption (4), although the direct acceleration of intermediary metabolism by these agents is well known (5) . In the intact working heart, on the other hand, norepinephrine induces an augmentation in MVO which is correlated with the increase in contractility as reflected in an increase in maximum velocity of fiber shortening and increased force de-velopment (6) . In all of these studies the assumption is made that a direct correlation of MVO 2 with energy utilization is present; that a steady state of aerobic metabolism exists; and that this relation is unaltered by norepinephrine. However, if norepinephrine were to uncouple oxidative phosphorylation or alter metabolic processes not associated with work production, these assumptions would not be entirely valid.
Adenosine triphosphate (ATP) appears to be the immediate source of energy for muscle contraction and along with creatine phosphate accounts for the readily available energy stores of the heart (7). Recent work has demonstrated that the utilization of these high-energy phosphate compounds by isolated heart muscle preparations can be directly correlated with mechanical activity (8) . This was accomplished by inhibiting the energy production of blocking both oxidarive phosphorylation and anaerobic glycolysis and subsequently determining the utilization of energy stores both at rest and during the performance of mechanical work.
The aim of the present study was to investigate the effect of norepinephrine on the direct conversion of chemical energy to mechanical work in heart muscle. To accomplish this, energy production was inhibited in papillary muscles isolated from the right ventricles of cats. The muscles were then allowed to perform work, and the utilization of chemical energy was correlated with the work performed.
Methods
Detailed descriptions of the methods used for studying the mechanical performance of the papillary muscle and calculations of contractile element work (8) , the chemical determinations of total creatine, creatine phosphate, ATP and inorganic phosphate (8, 9) , and calculations of total energy utilization (9) have been published.
To treat the papillary muscles with norepinephrine, IO-^M norepinephrine (1-norepinephrine bitartrate 1 ) was added to the bath 3 minutes prior to the administration of nitrogen and again added during the changing of the iodoacetic acid-Krebs iCalbiochem, Los Angeles, Calif. 90054, Lot 52786. solution to maintain this concentration. The norepinephrine solution was freshly prepared from dry powder. To determine whether norepinephrine would effect a peak mechanical response within 3 minutes in the presence of total metabolic blockade, it was added to a separate group of seven muscles treated with iodoacetic acid. Four of these muscles were contracting at a frequency of 12/min and three were "resting" (1 stimulus/min). The attainment of peak mechanical response was always demonstrated within 3 minutes.
The initial stores of creatine phosphate and ATP in each muscle were determined from the ratios of creatine phosphate to total creatine and ATP to total creatine as previously described (9) . These ratios in 20 control muscles resting 3 minutes in N 2 were 0.54± 0.02 and 0.34 ± 0.01 respectively while in 10 norepinephrine-treated muscles these ratios were 0.54 ± 0.03 and 0.36 ± 0.02 respectively.
The independent variables used in the regression analysis were (a) the number of contractions and (b) the contractile element work. Comparisons of the regression coefficients of these variables were made by an analysis of their respective beta weights (10) and by a test of the homogeneity of regressions (11) . To calculate resting energy utilization in the resting muscles a linear regression on time was performed with 'HP = creatine phosphate + ATP as the dependent variable.
All values are mean ± SEM.
Results
The addition of norepinephrine to the isolated papillary muscles used in this study consistently resulted in an increase both in the intrinsic speed of contraction, as reflected by the maximum rate of force development (dF/dt) at the apex of the length-active tension curve, and in the work performed per contraction.
In the control muscles, average dF/dt in the presence of metabolic blockade was 9% lower than that found at the end of the initial equilibration period, a difference which was not significant. However, in the presence of norepinephrine, average dF/dt was significantly increased by 21% (P < .005) compared to that observed during the initial equilibration period, while the work performed per contraction was increased from an average control value of 8.7 ± 0.4 g-cm/g to 13.7 ± 0.8g-cm/g Average peak tension development per contraction was also increased from 2.2 ±0.1 g/mm 2 to 3.4 ± 0.2 g/mm 2 . Because more work was performed per contraction by the norepinephrine-treated muscles than by the controls, the treated muscles were stimulated to contract an average of only 20.2 times per muscle and the control muscles an average of 34.4 times. Thus the total work performed by the norepinephrine-treated and the control muscles was similar, and excessive energy deCircuUHon Rtstarcb, Vol. XXII, June 1968 pletion in the treated muscles, which could have led to the development of rigor, was prevented.
RESTING ENERGY UTILIZATION
Resting energy utilization was evaluated by determining total energy stores (^~P = creatine phosphate + ATP) at the onset and after 3, 7, and 10 minutes of nitrogenaa'on. data obtained from 76 control muscles and 39 muscles receiving norepinephrine. The average initial store of energy (*-P) in the control muscles was 16.7 ±0.5 //.moles/g and was not changed following addition of norepinephrine (16.8±0.7 /imoles/g) (Fig. 1) . The resting rate of energy utilization was also not significantly altered by the addition of norepinephrine. This value was 0.77 ± 0.07 /xmoles/g/min in control muscles and 0.87 ±0.12 /xmoles/ g/min after norepinephrine (Fig. 1) .
EFFECT OF NOREPINEPHRINE ON ENERGY UTILIZATION OF ISOMETRIC CONTRACTIONS
Sixty-three control muscles and 40 norepinephrine-treated muscles were stimulated to contract a varying number of times and consequently performed varying amounts of mechanical work. 2 The average amount of energy used per muscle for contraction and the performance of work was obtained by subtracting resting energy (see above) from the total energy used. While the average norepinephrine-treated muscle used 115? as much energy as the average control muscle, it was stimulated to contract only 59% as many times and performed only 872 as much work (Table  I) a multiple regression analysis of the data was performed using total energy utilization (A 1 -P) as the dependent variable and the number of activations and contractile element work as the independent variables. This provided one time-related and one tension-related variable. The results of the regression analysis (Table 2) show that the regression model for both control and norepinephrine-treated muscles was highly significant as demonstrated by the multiple correlation coefficient (r) and analysis of variance of the regression.
The regression coefficients for both number of contractions and work performed were higher in the norepinephrine-treated muscles than in control muscles. Although a comparison of the beta weights of the individual coefficients did not reveal a significant difference between control and norepinephrine-treated muscles for either contractile element work (P>.25) or number of contractions (.2>P >.l), an analysis of the homogeneity of regressions demonstrated that the regression plane of the norepinephrine-treated muscles had a significantly steeper slope than that of controls (P < .01) indicating a significantly greater energy utilisation.
Because the amount of work performed per contraction by the norepinephrine-treated muscles was greater than that of the control muscles, the possibility arose that this difference, in itself, might account for an increase in energy utilization in the treated muscles. To test this possibility, the 36 control muscles with the greatest average work (or tension) output per contraction were compared to the 29 norepinephrine-treated muscles with the least work output per contraction. Under these conditions, work output per contraction was 11.2 g-cm/g in control muscles compared to 11.7 in norepinephrine-treated muscles. The average energy used, work performed, and number of contractions were calculated for the two groups. Although these norepinephrine-treated muscles contracted only 52% as many times and performed only 54% as much work as controls, they used 90% as much energy.
The possibility also arose that the fewer contractions performed by the norepinephrinetreated muscles may have accounted for thengreater energy utilization. To test this possibility, the 27 treated muscles which contracted the greatest number of times were compared with the 37 control muscles which contracted the least number of times. These two groups contracted a similar number of times (25.7 in controls compared to 25.0 in norepinephrine-treated muscles), and treated muscles performed 141% as much work as controls, but used 192% as much energy.
Discussion
There is general agreement that norepinephrine increases myocardial contractility, characterized in isolated heart muscle preparations (1) or in the intact heart (6) by an increase in the maximum velocity of isotonic shortening (Vm^) and in the maximum force of isometric contraction. This increase in Vnun is reflected in the isometric contraction by an increase in the maximum rate of force development (dF/dt) (12) . In addition, norepinephrine and other catecholamines increase the breakdown of glycogen to glucose through the activation of phosphorylase (13) and accelerate the liberation and oxidation of free fatty acids in the myocardium (14).
On the other hand, the effects of norepinephrine on myocardial oxygen consumption are controversial. It has long been known that when catecholamines induce an increase in the force of contraction, oxygen consumption of heart muscle increases (15, 16). Sarnoff et al. (J.7), using an isolated supported heart preparation, have reported that the increase in conCircuUtion Rtstarcb, Vol. XXII, Jtmt 1968 tractility induced by norepinephrine was unaccompanied by a change in MVOj as long as integrated ventricular pressure development ("tension-time index") was unchanged. However, it is likely that the increase in contractility produced by norepinephrine resulted in a significant decrease in heart size and a substantial fall in ventricular wall tension. In contrast, studies from this laboratory have shown that norepinephrine increases the MVOj of the heart, even though tension development is unchanged or even decreased (6, 18) . Indeed this increase in MVO2 which is required for augmenting the contractile state may now account for what had previously been termed the "oxygen wasting" effect of norepinephrine (19) .
The basis of this "oxygen wasting" effect is not clear. Several investigators (3, 20) have shown that catecholamines increase the MVO 2 of the arrested perfused heart and suggest that the increase in basal MVO 2 produced by epinephrine may be a result of an increase in the rate of oxidative metabolism. However, these increases in MV0 2 in the arrested heart are quite small in contrast to the increments in MVO 2 observed in the contracting myocardium (4, 18) .
Recently, it has been suggested that MVO 2 is determined by both tension development and the contractile state of the myocardium (6) , and the net change in MVO 2 has been attributed to the relative effects of norepinephrine on both of these variables. However, uncoupling of oxidative phosphorylation may have decreased the yield of high-energy phosphate compounds produced from oxidative metabolism and cannot be excluded as a contributing factor. This problem has been obviated in the design of the present study, since oxidative phosphorylation and the synthesis of high-energy phosphates has been blocked and only the direct utilization of highenergy phosphates in the presence of norepinephrine has been studied. Under these conditions no significant changes in initial stores or in the resting utilization of "HP has been observed. Further, it has been shown that high-energy phosphate utilization at any level of work is increased in the presence of norepinephrine, a finding which is consonant with the studies in intact heart (18) which have demonstrated an increase in MVO 2 even in the absence of an increase in tension development. This latter observation may be accounted for by an increase in high-energy phosphate utilization without necessarily invoking associated metabolic change. Therefore, norepinephrine directly increased energy release over and above that associated with augmented tension development. In addition, it is possible that that portion of increased energy utilization associated with contraction might be related to an increased release and reuptake of calcium ions from the sarcoplasmic reticulum.
One explanation for these findings may be found in studies on heat evolution from contracting skeletal muscle (21) . Hill has shown that the intrinsic speed of contraction (V m »i) determines the rate at which skeletal muscle uses energy at a given load. Accordingly, one might expect that an increase in contractility such as that produced by norepinephrine would increase the amount of v -P utilization in working heart muscle. This expectation has been realized in the present study, although these results, of themselves, do not prove the general relationship between increased energy utilization and increased contractility. However, these results in association with previous observations of increased MVO 2 in in vivo studies of the heart, do support this conclusion. The results imply that the so-called oxygen wasting effect of norepinephrine on heart muscle results from the increased utilization of energy associated with an increased contractile state.
